Nantahala Capital Management LLC Increases Stock Position in Savara Inc (NASDAQ:SVRA)

Nantahala Capital Management LLC lifted its position in Savara Inc (NASDAQ:SVRA - Free Report) by 45.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,525,259 shares of the company's stock after purchasing an additional 2,344,308 shares during the quarter. Savara comprises about 1.0% of Nantahala Capital Management LLC's investment portfolio, making the stock its 13th biggest position. Nantahala Capital Management LLC owned about 4.38% of Savara worth $23,103,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Cibc World Markets Corp purchased a new stake in shares of Savara during the 4th quarter worth approximately $33,000. XTX Topco Ltd purchased a new stake in Savara during the fourth quarter valued at $34,000. KLP Kapitalforvaltning AS bought a new position in Savara during the fourth quarter valued at $41,000. Hsbc Holdings PLC purchased a new position in shares of Savara in the 4th quarter worth $48,000. Finally, Jump Financial LLC bought a new stake in shares of Savara in the 4th quarter worth about $64,000. 87.93% of the stock is owned by institutional investors.

Savara Trading Up 4.3 %

Savara stock traded up $0.14 during midday trading on Friday, reaching $3.40. The stock had a trading volume of 706,717 shares, compared to its average volume of 1,296,987. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The firm has a market cap of $586.95 million, a price-to-earnings ratio of -7.91 and a beta of 0.52. Savara Inc has a 52-week low of $2.26 and a 52-week high of $5.31. The company has a fifty day moving average of $2.83 and a 200 day moving average of $3.06.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). The company had revenue of $0.27 million during the quarter. On average, analysts anticipate that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Savara in a research report on Friday, March 28th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $8.83.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.